Drastic Improvement in Hepatitis B/C Virus-induced Decompensated Liver Cirrhosis Treated by Total Management Consisting of Interventional Radiology, Endoscopy, and Pharmacotherapy-Reference-Cited by-同舟云学术

Drastic Improvement in Hepatitis B/C Virus-induced Decompensated Liver Cirrhosis Treated by Total Management Consisting of Interventional Radiology, Endoscopy, and Pharmacotherapy

Published:2022-11-01 Issue:21 Volume:61 Page:3217-3223
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Nishimura Tatsuro¹,Ishikawa Tsuyoshi¹,Kawamoto Daiki¹,Sasaki Ryo¹,Matsuda Takashi¹,Takami Taro¹

Affiliation:

1. Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/61/21/61_9240-21/_pdf

Reference24 articles.

1. 1. The Japan Society for Portal Hypertension. The General Rules for Study of Portal Hypertension. 3rd ed. Kanehara, Tokyo, 2013: 37-40.

2. 2. Shimizu H, Takatsuka K, Yoshida A, Yoshimatsu E, Matsui K, Iwabuchi S. Partial splenic embolization reverses insulin resistance in patients with liver cirrhosis. Intern Med 48: 747-751, 2009.

3. 3. Hirota S, Matsumoto S, Tomita M, Sako M, Kono M. Retrograde transvenous obliteration of gastric varices. Radiology 211: 349-356, 1999.

4. 4. Takaoka R, Miura K, Morimoto N, et al. Real-world efficacy and safety of 12-week sofosbuvir/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection. Hepatol Res 51: 51-61, 2021.

5. 5. Takehara T, Sakamoto N, Nishiguchi S, et al. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial. J Gastroenerol 54: 87-95, 2019.